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Abstract
Objectives—Annually, tens of thousands of children are brought to emergency departments for 
unsupervised medicine ingestions. We assessed whether adding flow restrictors to liquid medicine 
bottles can provide additional protection against unsupervised medicine ingestions by young 
children, even when the child-resistant closure is not fully secured.
Study Design—From April – May 2012, we conducted a block randomized trial with a 
convenience sample of 110 3- and 4-year-old children from 5 local preschools. Participants 
attempted to remove test liquid from an uncapped bottle with a flow restrictor and a control bottle 
without a flow restrictor (with either no cap or an incompletely-closed cap).
Results—Ninety-six percent (25/26) of open controls and 82% of incompletely-closed control 
bottles (68/83) were emptied within 2 minutes. Only 6% (7/110) of bottles with flow restrictors 
were emptied during the 10-minute testing period, none before 6 minutes. Overall, children 
removed less liquid from bottles with flow restrictors than from open or incompletely-closed 
controls (both P < .001). All children assigned open controls and 90% assigned incompletely-
closed controls removed ≥25 mL liquid. In contrast, 11% of children removed ≥25 mL liquid from 
uncapped bottles with flow restrictors. Older children (54 – 59 months) were more successful than 
younger children at removing ≥25 mL liquid (P = .002) from bottles with flow restrictors.
Conclusions—Findings suggest that adding flow restrictors to liquid medicine bottles limits the 
accessibility of their contents to young children and could complement the safety provided by 
current child-resistant packaging.
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The Poison Prevention Packaging Act (PPPA) of 1970 requires child-resistant packaging for 
most medicines in the United States.1 Since then, it has been estimated that child-resistant 
packaging has contributed to the prevention of hundreds, if not thousands, of pediatric 
deaths from unsupervised medication ingestions.2,3 Nevertheless, each year a half million 
calls are made to poison centers after young children find and ingest medicines.4 The 
number of emergency department (ED) visits for unsupervised medication ingestions is 
rising, with over 60,000 visits by young children annually.5,6 National data on the dose form 
of medicines involved in unsupervised ingestions are limited; however, approximately 80% 
of ED visits for ingestion of cough and cold medicines and 37% of visits for ingestion of 
acetaminophen products involved liquid medicines.7,8 A study of poison center calls found 
that liquid antibiotics prescribed for the child or a sibling were the most frequently ingested 
prescription medicines.9
Most ED visits for unsupervised medicine ingestions involve children younger than 5 years, 
with a peak incidence in 2-year-olds.10,11 While research on the circumstances surrounding 
these ingestions is limited, previous studies have shown that most occur in home 
environments,9,12-13 during a brief moment when the caregiver is not watching,13 and when 
medicines are not in their usual storage location.9,12-13 Children also gain access to 
medicines when caregivers do not use child-resistant packaging correctly (e.g., when caps 
are left off or are incompletely secured).9,14
The bottle-and-cap system commonly used in the United States for medication packaging 
requires the adult user to correctly re-engage the child-resistant closure each time the bottle 
is opened; otherwise the entire contents may be accessible. Flow restrictors, adapters added 
to the neck of a bottle to limit the release of liquid, have been suggested as a means to limit 
the amount of liquid medicine a young child could access even if the child-resistant closure 
is breached.5,15 Manufacturers began adding flow restrictors to over-the-counter (OTC) 
infants’ acetaminophen in 2011;16 however, the efficacy of flow restrictors in limiting 
accessibility of medicines to young children has not been assessed.
We sought to determine whether adding flow restrictors affects the proportion of preschool-
aged children who can access bottle contents, the amount accessed, and the time required for 
children to empty bottles compared with traditional bottles without flow restrictors.
METHODS
Study Design
The standard child test protocol for re-closeable packages outlined in the Poison Prevention 
Packaging Act (hereafter PPPA protocol)17 was modified to assess the efficacy of flow 
restrictors in limiting children's access to liquid medicines. The study was approved by the 
institutional review board (IRB) of the Centers for Disease Control and Prevention with 
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concurrence of the IRB of Emory University School of Medicine and the Research 
Oversight Committee of Grady Health System. Legal guardians provided written 
permission.
In the standard PPPA protocol, children participate in pairs and are asked to open a bottle 
with a child-resistant closure. In this study, children participated individually to ensure 
statistical independence between participants. Each child participated in two consecutive 
trials. In both trials, children were asked to “get everything out” of a bottle filled with a test 
liquid. To isolate the effect of flow restrictors and simulate improper child-resistant closure 
use, children were given an uncapped bottle with a flow restrictor (hereafter FR-bottle) for 
one trial. For the other trial, children were given a traditional bottle without a cap (open 
control) or with an incompletely-closed child-resistant cap (incompletely-closed control). To 
simulate what they might find at home, children were given the specific dosing device 
packaged with each bottle (dosing syringes with FR-bottles; dosing cups with control 
bottles).
Testers instructed children using a script based on the PPPA protocol. A second investigator 
recorded observations and timed the trials. If the child did not empty the bottle after 5 
minutes, the tester demonstrated removal of liquid to simulate what a child might observe at 
home. As in the PPPA protocol, the tester then reminded the child that teeth could be used 
and gave the child 5 additional minutes to remove liquid. Once both trials were complete, 
children were given age-appropriate messages about medicine safety.
Participants and Setting
The study was conducted in a convenience sample of 5 preschools in the Atlanta 
metropolitan area in April and May 2012. Although the PPPA protocol includes children 
aged 42 to 51 months, to facilitate enrollment, permission forms and information materials 
were distributed to guardians of children in classrooms with students aged 36 to 59 months. 
As in the PPPA protocol, children with overt illnesses, injuries, or physical or mental 
disabilities (assessed by guardians) were excluded. Guardians also confirmed that their 
children were English speakers and had no dietary restrictions or allergies to test liquid 
ingredients.
Test Products
Flow restrictors, bottles, and dosing devices that were currently in use or in production for 
use with oral OTC liquid medicines in the United States were provided by three 
manufacturers (referred to as designs A, B, or C). One flow restrictor was a rubber septum 
which reseals after syringe removal. Another design contained a small orifice engineered to 
match a corresponding syringe. The third design incorporated a “lock-and-key” mechanism 
which requires alignment of a specific syringe and a flow restrictor with a self-closing valve 
(Figure 1).
Bottles were filled to their intended volume (two 30 mL bottles; one 120 mL bottle) with a 
test liquid with similar fluid characteristics to medicines for which the flow restrictors were 
intended (NesQuik Strawberry Syrup). Incompletely-closed control bottles were prepared at 
the preschools immediately before testing by aligning the threading on bottles and caps and 
Lovegrove et al. Page 3
J Pediatr. Author manuscript; available in PMC 2015 November 20.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
rotating the “push-down-and-turn” caps 270 degrees clockwise, closing the bottle but not 
engaging the child-resistant locking mechanism.
Sample Size
The study was powered to detect a difference in the proportion of children who removed ≥5 
mL of test liquid from their FR-bottle compared to their control bottle. The authors predicted 
that ≥5 mL of liquid would be removed from 90% of open control bottles, 50% of 
incompletely-closed control bottles, and 15% of FR-bottles. We calculated that 30 
incompletely-closed / FR-bottle trials and 9 open control / FR-bottle trials for each of the 3 
FR-designs (A, B, and C) would be required to achieve 80% power at 5% significance level.
Sample Allocation
Children were assigned bottles for testing by randomizing a fixed block size of 12 pairs to 
attain: even distribution of the 3 FR-bottle designs (A, B, or C) at each site; even distribution 
of FR-bottle designs throughout the duration of the testing period at each site; and 3:1 
allocation of incompletely-closed (3) or open (1) control bottles across each FR-bottle 
design and the duration of the testing period at each site. Each assigned pairing of FR-bottle 
and control bottle was tested by two children. To ensure even distribution of testing order, 
one child tested an FR-bottle first and the other child tested a control bottle first. Prior to 
initiation of testing, each of the 5 sites was assigned a randomly selected block from 120 
possible block permutations. If a block assignment was not completed at one testing site, the 
untested bottle assignments were completed at a subsequent site where additional 
participants were available.
Outcome Measures
Data included observational measures. The primary outcome measures were the proportions 
of children who emptied bottles, removed ≥25 mL (≥5 typical doses), and removed ≥5 mL 
(≥1 typical dose) of test liquid from FR-bottles compared with incompletely-closed control 
bottles or open control bottles. To determine the amount of liquid removed, bottles were 
weighed before the trials, after 5 minutes, after the full 10-minute testing period, or when 
emptied. Weights were converted to mL for analysis.
Secondary outcome measures included time required to empty the bottles and proportion of 
liquid removed. For FR-bottles, amounts of liquid removed by age, sex, and site and 
approaches used to remove liquid from bottles were also assessed. Although our primary 
objective was to assess the 3 flow restrictor designs in combination, we also assessed the 
amount of test liquid removed for each FR-bottle design.
Statistical Analysis
For the primary outcomes, a McNemar test for paired proportions was used to assess 
differences in the proportion of children who removed specific amounts of test liquid from 
FR-bottles compared with each type of control bottle. The sign test was used to assess 
differences in the proportion of liquid that was removed from FR-bottles compared with 
control bottles. To determine whether age, sex, or site were associated with removal of 
specified amounts of liquid from FR-bottles, χ2 or Fisher exact tests were used. Two-sided P 
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values less than .05 were considered statistically significant. Data were analyzed using SAS 
version 9.2 (SAS Institute Inc).
RESULTS
Across the 5 sites, guardians of 120 children who met study inclusion criteria provided 
permission and 110 children (92%) participated; 5 were absent on testing days and 5 (all 3-
year-olds) refused to participate. Participants’ mean age was 49 months (range, 36-59 
months); 57% were boys (Table 1). Assignment to specific FR-bottle designs (A, B, or C) 
was similar by age and sex of participants and by site.
Children emptied incompletely-closed control bottles almost as frequently as they emptied 
open control bottles. Within 2 minutes, 96% of open controls (25/26) and 82% of 
incompletely-closed controls (68/83) were emptied (Figure 2). In contrast, none of the FR-
bottles were emptied before 6 minutes. Only 7 children (6%) emptied an FR-bottle within 
the full 10-minute testing period.
The proportions of children who removed specified amounts of test liquid were lower for 
each FR-bottle design compared with control bottles. Among children who tested FR-
designs A or B, 17% (6/36) removed ≥25 mL of liquid from each design (P < .001, 
compared to paired incompletely-closed controls). Twenty-two percent of children who 
tested design A (8/36) and one-third who tested design B (12/36) removed ≥5 mL of liquid 
(P < .001, and P = .001, respectively, compared to paired incompletely-closed controls). 
Only 1 child removed ≥5 mL of liquid (5.7 mL) from FR-design C (P <.001, compared to 
paired incompletely-closed controls).
Considering the 3 flow restrictor designs together, children removed less liquid from FR-
bottles than from open control or incompletely-closed control bottles (P < .001 by sign test). 
All children assigned open controls (26/26) and 90% assigned incompletely-closed controls 
(76/84) removed ≥25 mL of liquid, almost always during the first 5-minute test period 
(Table 2). Overall, 12 children (11%) removed ≥25 mL of liquid from FR-bottles, but only 1 
child did so during the first 5 minutes. Twenty-one children (19%) removed ≥5 mL of liquid 
from FR-bottles, but only 4 (4%) removed ≥5 mL within 5 minutes. Pairwise comparisons 
of removal of ≥25 mL liquid and ≥5 mL liquid from FR-bottles compared with each type of 
control bottle were statistically significant (P < .001).
Older children were more successful than younger children at removing ≥25 mL (P = .002) 
and ≥5 mL (P = .02) of liquid from FR-bottles. Of the 12 children who removed ≥25 mL of 
liquid, 10 were from the oldest age group (54 - 59 months). None of the youngest children 
(36 – 41 months) removed even 5 mL of liquid. No significant differences were detected in 
ability to remove ≥25 mL or ≥5 mL of liquid by sex or study site.
Children attempted a variety of strategies to remove liquid from FR-bottles, including using 
the dosing syringe (102/110; 93%); pouring, shaking, or squeezing from the bottle (66/110; 
60%); using teeth or attempting to manually remove the flow restrictor (50/110; 45%); and 
drinking from the bottle (4/110; 4%). All children who removed ≥25 mL used the syringe. 
One child also used teeth to remove the flow restrictor and subsequently emptied the bottle.
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DISCUSSION
Designing safety packaging that limits the amount of medication a child can remove even if 
a child-resistant closure is breached is a new approach to addressing unsupervised 
medication ingestions. To our knowledge, this is the first study to assess the efficacy of flow 
restrictors in limiting young children's access to liquid medicines. Compared with open 
bottles and bottles with incompletely-closed child-resistant caps, flow restrictors decreased 
the proportion of children who accessed liquid, and, for those who accessed liquid, flow 
restrictors decreased the amount of liquid that children accessed and increased the amount of 
time required to empty a bottle. Our findings suggest that adding flow restrictors to bottles 
with child-resistant closures could provide a complementary dose-limiting barrier for liquid 
medicines.
Standard child-resistant packaging is designed to prevent, or at least delay, young children 
from opening bottles for a “reasonable time” to increase the likelihood that caregivers may 
intervene.19 Two limitations of current re-closeable child-resistant packaging are reliance on 
caregivers to correctly re-secure the cap after every use and accessibility of the entire bottle 
contents once the cap is removed. Although data are limited, imperfect practices have been 
implicated in unsupervised ingestions,9,14 and in at least one study, 80% of ingestions 
occurred within 5 minutes.13 In this trial, when the “push-down-and-turn”-style child-
resistant cap was not completely re-secured, 82% of children emptied their bottles within 2 
minutes. The addition of flow restrictors delayed children from accessing bottle contents, 
even when there were no child-resistant caps on bottles. None of the children emptied an 
FR-bottle until over 6 minutes had elapsed (and after demonstration of liquid removal); only 
6% emptied their FR-bottles within the full 10-minute testing period. The added time 
required to access contents from FR-bottles may provide an opportunity for caregiver 
intervention before substantial amounts are removed. Furthermore, study participants were 
asked to remove all liquid from their bottles and, as specified in the PPPA protocol, they 
were gently but repeatedly encouraged to keep trying. In a home environment, at least some 
young children might stop trying without such encouragement.
Flow restrictors also limited the dose that preschool-aged children accessed. For a 2-3 year-
old child, the recommended dose of infants’ acetaminophen is 5 mL. Given an uncapped 
bottle, 10 minutes, and gentle encouragement, flow restrictors prevented 81% of participants 
from removing even a single 5 mL dose and 89% from removing 5 or more doses (≥25 mL). 
In contrast, an incompletely-closed control bottle prevented only 10% of participants from 
removing 5 or more doses.
Expanding the use of flow restrictors beyond infants’ acetaminophen could reduce the 
severity of ingestions and the number of children referred for costly emergency evaluation 
and treatment. The addition of flow restrictors on infants’ acetaminophen bottles may reduce 
parental distress and unnecessary emergency visits, but the reformulated concentration (160 
mg/5 mL) and small bottle size (30 mL) limit the maximum available dose to non-toxic 
levels for most children. However, if a child younger than 5 years ingested of a full 120 mL 
bottle of liquid children's acetaminophen, he or she would likely be referred for emergency 
evaluation.20 The threshold dose for emergency evaluation is lower for other children's OTC 
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medicines. Children younger than 5 years would likely be referred to an ED for suspected 
ingestion of half of a 120 mL bottle of children's diphenhydramine 21 and for a fifth of a 120 
mL bottle of some dextromethorphan products.22
This study focused on assessing innovative safety packaging used with OTC pediatric liquid 
medicines because these medicines are intended for the children who are most at risk for 
unsupervised ingestions. Of course, children get into medicines other than OTC pediatric 
liquids. A study by Bailey et al suggests that current child-resistant closures may not provide 
sufficient protection for some medications, particularly opioids, that can be lethal to a young 
child at a single dose.23 Prescription medicines that are harmful to young children at low 
doses,24 such as opioid-containing liquid medicines, may be good candidates for 
incorporating flow restrictors in addition to child-resistant closures.
Our study has several limitations. First, to isolate the effect of flow restrictors and replicate 
the circumstances of improper use of child-resistant closures, we tested flow restrictors 
alone, without child-resistant caps. In practice, medicine bottles with flow restrictors are 
packaged with child-resistant closures, so we likely underestimated the efficacy for 
concurrent use of both safety barriers. Second, we did not assess the usability or 
acceptability of FR-bottles and accompanying dosing syringes with adults. While studies 
have shown that adults measure doses more accurately using oral syringes than with other 
devices,25,26 usability and acceptability of each design should be assessed. As with some 
early child-resistant closures, if adults cannot use them with relative ease, they circumvent 
them.27 Third, our results may not be generalizable to all FR-designs or all medication 
formulations and viscosities. Because we assessed products where a specific flow restrictor 
is mated to a bottle of a specific size, the effect of bottle size cannot be separated from FR-
design. Specific flow restrictors, bottles, and their intended contents should be compatible 
and design-contents combinations should have efficacy demonstrated. Fourth, this study was 
not designed to assess differences in performance among FR-designs; however, findings 
from this study and feedback from user experience may inform future design refinements. 
Fifth, preschools were located in urban and suburban settings and served children from a 
range of socio-economic groups, but we did not assess the knowledge or experience of 
individual children with child-resistant closures or flow restrictors prior to study 
participation. Lastly, the experimental study design may also affect generalizability to all 
children and home settings. We were surprised that only 4 children tried to drink from FR-
bottles, but we suspect that observation by adults may have discouraged them. The apparent 
reluctance to drink directly from bottles may also have been related to the children's age. In 
general, study participants were slightly older than the ages specified in the PPPA protocol 
(42-51 months). Younger children may have been more likely to put the bottles in their 
mouths, but younger children have not participated reliably in previous studies.28,29 
Nonetheless, because none of the youngest children in our study (36-41 months) removed 
even 5 mL of liquid and most ED visits for unsupervised medicine ingestion are by still 
younger children (1- and 2-year-olds),10,11 we likely underestimated the efficacy of flow 
restrictors for the children who are at greatest risk.
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Conclusions
Child-resistant caps are efficacious in delaying children from accessing medicines only 
when completely re-secured after every use. Our findings suggest that flow restrictors may 
limit the amount of liquid medicine that a young child can access even when the child-
resistant closure is not fully secured; future studies might focus on application of similar 
passive engineering and dose-limiting features to solid-dose medicine packaging. 
Importantly, flow restrictors are designed as a secondary barrier and caregivers should not 
rely on flow restrictors alone. While improved packaging can limit ingestions, educational 
interventions should continue to highlight the importance of locking child-resistant caps 
after every use and storing medicines up and away and out of sight of young children.30
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Figure 1. Flow Restrictor Designs
Flow restrictor designs viewed from an angle. These adapters are added to the neck of a 
standard liquid medicine bottle to limit the release of liquid. The flow restrictor depicted (*) 
is no longer on the marketed product.18 It has been enhanced to minimize the risk of the 
flow restrictor being pushed into the bottle when inserting the syringe.
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Figure 2. 
Time Required for Children to Empty Open Control Bottles, Incompletely-closed Control 
Bottles, and Bottles with Flow Restrictorsa
Abbreviations: FR-bottle, uncapped bottle with a flow restrictor
a
 Child testing of control bottles was ended and the bottles were considered empty when the 
tester noted pauses ≥1 second between drops of test liquid when fully inverted. Weighing of 
control bottles confirmed removal of ≥88% of test liquid in all cases. Flow restrictor bottles 
were manually inspected when a child who had been successfully removing test liquid 
appeared to be unable to remove additional amounts. If a bottle appeared to be empty by 
manual inspection, testing was ended. Weighing of flow restrictor bottles confirmed removal 
of ≥88% of test liquid in all cases.
b
 Time not recorded for 1 trial with an incompletely-closed control bottle.
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Table 1
Participant Demographics
Characteristic No. (%) of Participants
Age (months)
    36 - 41 14 (13)
    42 - 47 37 (34)
    48 - 53 23 (21)
    54 - 59 36 (33)
Sex
    Female 47 (43)
    Male 63 (57)
Site
    1 22 (20)
    2 22 (20)
    3 26 (24)
    4 18 (16)
    5 22 (20)
Total 110 (100)
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